Stereotaxis reported second quarter 2026 revenue of $7.7 million, a decline from $8.8 million in the prior year period. System revenue fell to $1.5 million due to the absence of robotic system deliveries, while recurring revenue rose to $6.2 million, driven by new robotic catheter sales that surpassed $1 million and initial Synchrony digital operating room system sales following FDA clearance. The company completed its acquisition of Robocath, strengthening its endovascular robotics portfolio. Operating loss widened to $4.6 million compared to $4.0 million in the prior year, with a net loss of $4.5 million. Cash and cash equivalents stood at $10.5 million with no debt. Management anticipates recurring revenue growth to approximately $7 million in Q3 and $8 million in Q4 2026, targeting cash flow profitability in the first half of 2027. Stereotaxis operates in the medical device industry, specializing in surgical robotics for minimally invasive endovascular interventions.

Stereotaxis, Inc. completed its acquisition of Robocath, a French company, on July 7, 2026. The transaction involved the issuance of 6,269,628 shares of common stock and includes potential earnout consideration of up to $25 million in cash or shares. Stereotaxis, Inc. is a medical device company specializing in in situ magnetic navigation technology.

Stereotaxis, Inc. completed its acquisition of Robocath, a French company, on July 7, 2026, for approximately $20 million in cash and common stock. The transaction involved the issuance of 1,469,485 shares of common stock and 4,575,143 pre-funded warrants, alongside 225,000 shares issued to a financial advisor. Additional earnout performance targets could trigger up to $25.0 million in aggregate contingent consideration. Stereotaxis, Inc. is a medical technology company specializing in in vivo robotic magnetic navigation systems.